Enzon Reports Third Quarter 2006 Results
|
|
- Kerrie Francis
- 5 years ago
- Views:
Transcription
1 November 2, 2006 Enzon Reports Third Quarter 2006 Results Turnaround Makes Visible Progress BRIDGEWATER, N.J., Nov 02, 2006 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN) today announced its financial results for the third quarter of For the three months ended September 30, 2006, Enzon reported net income of $2.2 million or $0.05 per diluted share, as compared to a net loss of $5.8 million or $(0.13) per diluted share. "We are pleased to report another solid quarter, but more importantly, we are enthusiastic about the Company's momentum toward rebuilding the pipeline, maximizing our current brands and recruiting top talent to lead the organization in achieving the next level of success," said Jeffrey H. Buchalter, chairman and chief executive officer of Enzon. "Over the past year, we have been able to leverage and modernize the Company's core asset, PEGylation technology, by integrating it with novel oncology candidates, setting the stage for a new, innovative pipeline from the Company." Company Updates: -- The Company's rhmbl program expands with the approval of an additional Investigational New Drug (IND) application for use in the prevention and treatment of severe infections in patients with low levels of MBL undergoing liver transplant treatment. -- The Company's Santaris Pharma A/S collaboration, which was established in July of this year, is on track and the Company anticipates filing an IND for the HIF-1 alpha antagonist by the end of The Company expects to have data presented at upcoming medical conferences on three of its research and development projects. These include: rhmbl, recombinant human Manose Binding Lectin for immuno-suppressed patients, Oncaspar(R), a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase, and PEG-SN38, a PEGylated form of the active moiety of CPT-11 or Camptosar(R). Financial Results Revenues The following table reflects the revenues generated by product and segment for each of the three-month periods ended September 30, 2006 and Three Months Ended (in thousands) September 30, September 30, % Change Products Oncaspar $7,418 $5,789 28% Depocyt 2,000 2,334 (14%) Abelcet 8,986 11,113 (19%) Adagen 6,891 5,940 16% Total Products 25,295 25,176 n.m. Royalties 18,705 15,478 21% Contract Manufacturing 1,856 3,393 (45%) Total Revenues $45,856 $44,047 4% ===============
2 Products Segment Sales from the products segment, comprised of Oncaspar(R), Depocyt(R), Abelcet(R), and Adagen(R), increased slightly to $25.3 million for the three months ended September 30, 2006, from $25.2 million for the three months ended September 30, Sales of Oncaspar grew to $7.4 million or 28 percent for the three months ended September 30, 2006, as compared to $5.8 million for the three months ended September 30, The growth of Oncaspar is mainly attributable to its adoption in certain protocols by hospitals and cooperative groups. On July 25, 2006, the Company announced the approval of Oncaspar for the first line treatment of acute lymphoblastic leukemia (ALL). Sales of Depocyt, a sustained-release formulation of the chemotherapeutic agent cytarabine arabinoside or ara-c used for the treatment of lymphomatous meningitis, decreased to $2.0 million or 14 percent for the three months ended September 30, 2006, as compared to $2.3 million for the three months ended September 30, Sales of Abelcet in the U.S. and Canada, a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections, for the three months ended September 30, 2006 were $9.0 million, down 19 percent as compared to $11.1 million for the three months ended September 30, The decrease was primarily the result of expected competition from current and newly launched therapeutics in the anti-fungal market. Sales of Adagen, an enzyme replacement therapy used to treat adenosine deaminase (ADA) deficiency in patients with severe combined immuno-deficiency disease, increased 16 percent to $6.9 million for the three months ended September 30, 2006, as compared to $6.0 million for the three months ended September 30, This market has a very small number of patients so quarter-to-quarter variability is not uncommon. Royalties Segment Revenues from the Company's Royalties segment for the three months ended September 30, 2006 were $18.7 million, as compared to $15.4 million for the three months ended September 30, 2005, an increase of 21 percent. Royalties on PEG- INTRON, marketed by Schering-Plough, continue to comprise the majority of our royalty revenue. Schering-Plough has recently indicated that they anticipate a decline in PEG-INTRON sales in Japan as new patient enrollment moderates and competition increases. Contract Manufacturing Segment The Company's revenues from its Contract Manufacturing segment were $1.9 million for the three months ended September 30, 2006, as compared to $3.4 million in the corresponding period of the prior year. This includes contract manufacturing revenues related to services the Company provides for customers who require injectable products, such as Abelcet for markets outside of Canada and the U.S. During the quarter, the revenue reconciliation for two contract manufacturing products resulted in a reduction of revenue of $1.2 million. The timing of production of another product Enzon manufactures also resulted in lower revenues. Research and Development The Company's research and development expenses were $10.6 million for the three months ended September 30, 2006, as compared to $5.3 million for the three months ended September 30, The increase was attributable to initiation of programs in Research and development expenses last year was impacted by the restructuring that occurred in the second quarter of Enzon is committed to investing in research and development to build a leading oncology business through the continued development of its current portfolio, reinforcing its position as a scientific leader in PEGylation through its Customized Linker Technology(TM) platforms and strategic in-licensing of innovative cancer programs, as demonstrated by the Company's strategic collaboration with Santaris reported last quarter. Selling, General and Administrative Selling, general and administrative expenses increased to $14.3 million for the three months ended September 30, 2006, as compared to $11.7 million for the three months ended September 30, The increase is mainly attributable to the costs associated with the Company's debt refinancing completed this quarter. The Company will continue to invest in selling, marketing, and other initiatives to further its objective of delivering long-term value, including improving its top-line performance by investing in its commercial operations. Amortization of Acquired Intangible Assets
3 Amortization expense decreased by $3.1 million to $184 thousand for the three months ended September 30, 2006, as compared to $3.3 million for the three months ended September 30, The decrease is a result of the Abelcet intangible write-down which occurred in December Acquired In-Process Research and Development In August 2006, we paid $8.0 million for worldwide rights to develop and commercialize certain RNA antagonists. During the third quarter of last year, the Company paid $10.0 million for the rights to the clinical development of recombinant human Mannose-Binding Lectin. Other Income (Expense) Net other income (expense) is comprised of investment income, interest expense, and other non-operating expenses. The Company reported other income of approximately $1.8 million for the three months ended September 30, 2006, as compared to other expense of nearly $6.3 million in the same period in the prior year. In July 2006, the Company completed its debt refinancing by repurchasing $137.6 million of the 4.5% notes due in 2008, which resulted in a gain of $4.8 million. This gain was offset by the write-off of $1.2 million in deferred offering costs associated with the 2008 convertible notes repurchased. In 2005, the Company reported a loss of $3.5 million related to the maturing of a financial instrument the Company formed to reduce its investment risk associated with 1.5 million shares of NPS Pharmaceuticals, Inc. (NPS) common stock received in June Income Taxes For the three months ended September 30, 2006, the Company recognized a nominal amount of state and Canadian tax liabilities. For 2006, the estimated effective annual U.S. income tax rate is nominal due to the Company's projected taxable income and availability of net operating loss carryforwards. Cash and Investments Total cash reserves, which include cash, cash equivalents, short-term investments and marketable securities, were $240.4 million as of September 30, 2006, as compared to $226.6 million as of December 31, Positive operating cash flows for the nine-month period ended September 30, 2006 and cash proceeds from the sale of Nektar common stock the Company owned contributed to the increase in cash. Offsetting these cash inflows was the January payment to Sanofi-Aventis of $35.0 million relating to a reduction of the Oncaspar royalty rate. Reconciliation of GAAP net income (loss) to adjusted net income (loss) For the three months ended September 30, 2006, Enzon reported an adjusted net loss of $1.3 million or $(0.03) per diluted share, as compared to an adjusted net loss of $2.3 million or $(0.05) per diluted share for the three months ended September 30, The following table reconciles the Company's net income (loss) and net income (loss) per diluted share as determined in accordance with U.S. generally accepted accounting principles (GAAP) to its adjusted net loss and adjusted net loss per diluted share for the three months ended September 30, 2006 and 2005: Three Months Ended (in thousands, except per-share amounts) September 30, 2006 September 30, 2005 Net Net income loss Net (loss) per per income diluted Net diluted (loss) share Loss share GAAP net income (loss) $2,238 $0.05 $(5,766) $(0.13) Net adjustments to GAAP: -- Net realized gain (3,569) (0.08) related to the repurchase of debt (1) -- Net realized loss - - 3,
4 related to the sale of NPS common stock (2) Adjusted net loss (3) $(1,331) $(0.03) $(2,306) $(0.05) (1) The Company's adjusted financial results for the third quarter of 2006 exclude a gain related to the repurchase of the 4.5% Notes at a price of $965 (plus accrued interest) for each $1,000 principal amount of notes tendered, offset by a write-off of related debt offering costs. (2) The Company's adjusted financial results for the September quarter of 2005 exclude a net-of-tax realized loss of $3.5 million related to the maturing of a financial instrument the Company formed to reduce its investment risk associated with 1.5 million shares of NPS Pharmaceuticals, Inc. (NPS) common stock received in June The Company received the common stock under a merger termination agreement with NPS. (3) Adjusted net loss and adjusted net loss per diluted share, as the Company defines them, may differ from similarly named measures used by other entities, and consequently, could be misleading unless all entities calculated and defined such items in the same manner. The Company believes that investors' understanding of its performance is enhanced by disclosing adjusted net income (loss) and adjusted net income (loss) per diluted share reflecting adjustments for certain items that the Company deems to be non-recurring. Conference Call and Webcast Enzon will be hosting a conference call November 2, 2006 at 9:00am E.S.T. All interested parties may access the call by using the following information: Domestic Dial-In Number: (866) International Dial-In Number: (416) Access Code: Enzon Enzon's conference call will also be webcast in a "listen only" mode via the Internet at Additionally, for those parties unable to listen at the time of Enzon's conference call, a telephone rebroadcast will be available following the call from November 2, 2006, at approximately 12:00 p.m. E.S.T. This rebroadcast will end on November 9, 2006, at approximately 11:59 p.m. E.S.T. The rebroadcast may be accessed using the following information: Domestic Dial-In Number: (866) International Dial-In Number: (416) Access Code: About Enzon Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets Abelcet(R), Oncaspar (R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology(TM) PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon complements its internal research and development efforts with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. The Company also engages in contract manufacturing opportunities with third parties to improve its efficiency. Further information about Enzon and this press release can be found on the Company's web site at
5 There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon's products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our transition report on Form 10-K for the six-month period ended December 31, 2005 and our quarterly reports on Form 10-Q. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information. (Financial information to follow) Enzon Pharmaceuticals, Inc. and Subsidiaries Consolidated Statements of Operations Three Months ended September 30, 2006 and 2005 (In thousands, except per share data) (Unaudited) September 30, September 30, Revenues: Product sales, net $25,295 $25,176 Royalties 18,705 15,478 Contract manufacturing 1,856 3,393 Total revenues 45,856 44,047 Costs and expenses: Cost of product sales and contract manufacturing 12,141 11,964 Research and development 10,599 5,319 Selling, general and administrative 14,299 11,697 Amortization of acquired intangible assets 184 3,348 Acquired in-process research and development 8,000 10,000 Total costs and expenses 45,223 42,328 Operating income 633 1,719 Other income (expense): Investment income, net 2,831 1,632 Interest expense (5,912) (4,946) Other, net 4,813 (3,059) 1,732 (6,373) Income (loss) before income tax provision 2,365 (4,654) Income tax provision 127 1,112 Net income (loss) $2,238 $(5,766) Earnings (loss) per common share - basic $0.05 $(0.13)
6 Earnings (loss) per common share - diluted $0.05 $(0.13) Weighted average shares - basic 43,590 43,486 Weighted average shares - diluted 43,590 43,486 Enzon Pharmaceuticals, Inc. and Subsidiaries Condensed Consolidated Balance Sheets September 30, 2006 and December 31, 2005 (In thousands) (Unaudited) September 30, December 31, Assets Current assets: Cash and short-term investments $169,985 $164,518 Accounts receivable, net 11,798 14,087 Inventories 18,381 16,014 Other current assets 6,211 12,596 Total current assets 206, ,215 Property and equipment, net 37,576 34,978 Other assets: Marketable securities 70,458 62,059 Amortizable intangible assets, net 63,093 34,154 Other long-term assets 6,873 2, ,424 99,152 Total assets $384,375 $341,345 Liabilities and Stockholders' Deficit Current and other liabilities $31,087 $31,315 Notes payable 397, ,000 Stockholders' deficit (44,354) (83,970) Total liabilities and stockholders' deficit $384,375 $341,345 Common shares outstanding 43,877 43,787 SOURCE: Enzon Pharmaceuticals, Inc. Enzon Pharmaceuticals, Inc. EVP, Finance and Chief Financial Officer Craig Tooman, Copyright Business Wire 2006 News Provided by COMTEX
Enzon Reports Third Quarter 2010 Results
Enzon Reports Third Quarter 2010 Results -- Results reflect continued investment in innovative oncology pipeline and increased operating efficiencies -- BRIDGEWATER, N.J., Nov 02, 2010 (BUSINESS WIRE)
More informationINC Research/inVentiv Health Reports Third Quarter 2017 Results
Exhibit 99.1 FOR IMMEDIATE RELEASE INC Research/inVentiv Health Reports Third Quarter Results Highlights Net service revenue of 592.2 million and 1,102.4 million for the three and nine months ended, respectively.
More informationAstex Pharmaceuticals Reports 2013 Second Quarter Financial Results
News Release Astex Pharmaceuticals Reports 2013 Second Quarter Financial Results SGI-110 clinical data presented at EHA for Phase 1 MDS patients Second quarter royalty revenue increased 15% to $16.6 million
More informationENZON PHARMACEUTICALS INC
ENZON PHARMACEUTICALS INC FORM 10-Q (Quarterly Report) Filed 5/15/2001 For Period Ending 3/31/2001 Address 685 ROUTE 202/206 BRIDGEWATER, New Jersey 08807 Telephone 732-980-4500 CIK 0000727510 Industry
More information2008 Fourth Quarter Financial Results Year-Over-Year:
Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG): REVLIMID #1 Therapy in Multiple Myeloma
More informationMcKESSON REPORTS FISCAL 2015 THIRD-QUARTER RESULTS
McKESSON REPORTS FISCAL 2015 THIRD-QUARTER RESULTS Revenues of $47 billion for the third quarter, up 37%. Third-quarter GAAP earnings per diluted share from continuing operations of $2.01, up 187%. Third-quarter
More informationMcKESSON REPORTS FISCAL 2012 SECOND-QUARTER RESULTS
McKESSON REPORTS FISCAL 2012 SECOND-QUARTER RESULTS Revenues of $30.2 billion for the second quarter, up 10%. Second-quarter GAAP earnings per diluted share of $1.18. Second-quarter per diluted share of
More informationHealthStream Announces Third Quarter 2010 Results
HealthStream Announces Third Quarter 2010 Results NASHVILLE, Tenn., Oct 25, 2010 (BUSINESS WIRE) -- HealthStream, Inc. (NASDAQ: HSTM), a leading provider of learning and research solutions for the healthcare
More informationOwens & Minor Reports 3rd Quarter 2017 Financial Results
November 1, 2017 Owens & Minor Reports 3rd Quarter 2017 Financial Results Owens & Minor to acquire the Surgical & Infection Prevention Business of Halyard Health in a $710 million transaction RICHMOND,
More informationQuinStreet Reports Q1 Financial Results and Corporate Restructuring
November 9, 2016 QuinStreet Reports Q1 Financial Results and Corporate Restructuring Company Announces Stock Repurchase Program FOSTER CITY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- QuinStreet, Inc. (Nasdaq:QNST),
More informationMcKESSON REPORTS FISCAL 2015 SECOND-QUARTER RESULTS
McKESSON REPORTS FISCAL 2015 SECOND-QUARTER RESULTS Revenues of $44.8 billion for the second quarter, up 36%. Second-quarter GAAP earnings per diluted share from continuing operations of $2.05, up 13%.
More informationCelgene Reports First Quarter 2009 Operating and Financial Results. SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, Celgene Corporation (NASDAQ: CELG):
Celgene Reports First Quarter 2009 Operating and Financial Results SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, 2009-- Celgene Corporation (NASDAQ: CELG): REVLIMID Continues Gains in Multiple Myeloma Both in
More informationANTARES PHARMA REPORTS THIRD QUARTER 2018 OPERATING AND FINANCIAL RESULTS. The Company Posts Record Quarterly Revenue Of $17.
ANTARES PHARMA REPORTS THIRD QUARTER 2018 OPERATING AND FINANCIAL RESULTS The Company Posts Record Quarterly Revenue Of $17.9 Million EWING, NJ, November 6, 2018 -- Antares Pharma, Inc. (NASDAQ: ATRS)
More informationANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS
ANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS First Quarter Revenue Growth Driven By A Nine Percent Increase In Product Sales EWING, NJ, May 8, 2018 -- Antares Pharma, Inc.
More informationEurand Reports Recent Developments and Fourth Quarter and Full-Year 2008 Financial Results
Eurand Reports Recent Developments and Fourth Quarter and Full-Year 2008 Financial Results AMSTERDAM, THE NETHERLANDS, Mar 05, 2009 (MARKET WIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX) Recent
More informationXOMA Reports First Quarter 2006 Results *********************************************************************
News Release Paul Goodson Investor Relations Tel: (510) 204-7270 XOMA Reports First Quarter 2006 Results ********************************************************************* Berkeley, CA May 10, 2006
More informationMGC Diagnostics Corporation Reports Fiscal 2017 Third Quarter Results
MGC Diagnostics Corporation 350 Oak Grove Parkway Saint Paul, MN 55127 Telephone: (651) 484-4874 Facsimile: (651) 484-4826 FOR IMMEDIATE RELEASE MGC Diagnostics Corporation Reports Fiscal 2017 Third Quarter
More informationUnder Armour Reports First Quarter Results
May 1, 2018 Under Armour Reports First Quarter Results First Quarter Revenue up 6 Percent; Company Reiterates Full Year 2018 Outlook BALTIMORE, May 1, 2018 /PRNewswire/ -- Under Armour, Inc. (NYSE: UA,
More informationMcKESSON REPORTS FISCAL 2013 SECOND-QUARTER RESULTS
McKESSON REPORTS FISCAL 2013 SECOND-QUARTER RESULTS Revenues of $29.9 billion for the second quarter, down 1%. Second-quarter GAAP earnings per diluted share of $1.67, up 42%. Second-quarter per diluted
More informationCantel Medical Reports Financial Results for its First Quarter Fiscal Year 2019
Cantel Medical Reports Financial Results for its First Quarter Fiscal Year 2019 November 29, 2018 Medical segment leads with strong double-digit growth - Net sales of $225.6M, up 6.0%, with organic sales
More informationANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS
ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue The Company Reaffirms 2019 Revenue Guidance
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) December 31, 2015 December 31, 2014 December 31, 2015 December 31, 2014 Revenues: Subscription $ 244,702
More informationAkorn Reports Second Quarter 2011 Financial Results -Revenues of $32.1 million and Adjusted EBITDA of $10.6 million- -Raises Outlook for 2011-
At the Company: Akorn, Inc. Tim Dick, Chief Financial Officer (847) 279-6150 FOR IMMEDIATE RELEASE Akorn Reports Second Quarter 2011 Financial Results -Revenues of $32.1 million and Adjusted EBITDA of
More informationHealthStream Announces First Quarter 2011 Results
HealthStream Announces First Quarter 2011 Results NASHVILLE, Tenn.--(BUSINESS WIRE)-- HealthStream, Inc. (NASDAQ: HSTM), a leading provider of learning and research solutions for the healthcare industry,
More informationHealthStream Announces Second Quarter 2010 Results
HealthStream Announces Second Quarter 2010 Results NASHVILLE, Tenn., Jul 26, 2010 (BUSINESS WIRE) -- HealthStream, Inc. (NASDAQ: HSTM), a leading provider of learning and research solutions for the healthcare
More informationCantel Medical Reports Financial Results for its Third Quarter Fiscal Year 2018
Cantel Medical Reports Financial Results for its Third Quarter Fiscal Year 2018 May 31, 2018 Strong performance across all divisions fuels growth - Net sales of $217.3M, up 13.1%, with organic sales growth
More informationTHERAPEUTICSMD REPORTS FIRST QUARTER 2014 RESULTS. Management to Host Conference Call at 4:30 EDT Today
FOR IMMEDIATE RELEASE THERAPEUTICSMD REPORTS FIRST QUARTER 2014 RESULTS Management to Host Conference Call at 4:30 EDT Today Boca Raton, FL, May 5, 2014 TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women s
More informationCryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma
Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma - - - Biopharma revenue up 69% year-over-year; 33 new clinical trials supported during second quarter IRVINE, CA Aug 8, 2017
More informationicad REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS
icad REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS PowerLook Tomo Detection Version 2.0 Submitted for FDA Approval Conference call today at 4:30 p.m. ET NASHUA, N.H. (August 14, 2018) icad, Inc. (NASDAQ:
More informationNektar Therapeutics Reports Financial Results for the Third Quarter of 2017
November 7, 2017 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017 SAN FRANCISCO, Nov. 7, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial
More informationCPSI Announces Third Quarter 2018 Results
CPSI Announces Third Quarter 2018 Results November 1, 2018 Company Announces Quarterly Cash Dividend of $0.10 Per Share MOBILE, Ala.--(BUSINESS WIRE)--Nov. 1, 2018-- CPSI (NASDAQ: CPSI): Highlights for
More informationMcKESSON REPORTS FISCAL 2017 FIRST-QUARTER RESULTS
McKESSON REPORTS FISCAL 2017 FIRST-QUARTER RESULTS Revenues of $49.7 billion for the first quarter, up 5% year-over-year. First-quarter GAAP earnings per diluted share from continuing operations of $2.88,
More informationHealthStream Announces Fourth Quarter & Full Year 2011 Results
HealthStream Announces Fourth Quarter & Full Year 2011 Results NASHVILLE, Tenn.--(BUSINESS WIRE)-- HealthStream, Inc. (NASDAQ: HSTM), a leading provider of learning and research solutions for healthcare
More informationMcKESSON REPORTS FISCAL 2016 FIRST-QUARTER RESULTS
McKESSON REPORTS FISCAL 2016 FIRST-QUARTER RESULTS Revenues of $47.5 billion for the first quarter, up 9%. First-quarter GAAP earnings per diluted share from continuing operations of $2.50, up 42%. First-quarter
More informationMcKESSON REPORTS FISCAL 2017 SECOND-QUARTER RESULTS AND REVISED FISCAL 2017 OUTLOOK
McKESSON REPORTS FISCAL 2017 SECOND-QUARTER RESULTS AND REVISED FISCAL 2017 OUTLOOK Revenues of $50.0 billion for the second quarter, up 2% year-over-year. Second-quarter GAAP earnings per diluted share
More informationMelinta Therapeutics Reports First Quarter 2018 Financial Results
Melinta Therapeutics Reports First Quarter 2018 Financial Results Strong Product Sales Performance Across Entire Portfolio Continuing to Optimize Operations to Achieve Cost Synergies Important Achievements
More informationUnder Armour Reports Third Quarter Results; Updates Full Year 2018 Outlook
Under Armour Reports Third Quarter Results; Updates Full Year 2018 Outlook October 30, 2018 BALTIMORE, Oct. 30, 2018 /PRNewswire/ -- (NYSE: UA, UAA) today announced financial results for the third quarter
More informationGW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018 February 26, 2019 Epidiolex (cannabidiol) oral solution (CV), first FDA-approved plant-derived
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) September 30, 2016 September 30, 2015 September 30, 2016 September 30, 2015 Revenues: Subscription $ 318,934
More informationIntermolecular Announces Third Quarter 2017 Financial Results
Intermolecular Announces Third Quarter 2017 Financial Results SAN JOSE, Calif., November 2, 2017 -- Intermolecular, Inc. (NASDAQ: IMI) today reported results for its Third Quarter ended September 30, 2017.
More informationTrimble Reports First Quarter Revenue of $289.0 Million and Non-GAAP Earnings Per Share of $0.28
Trimble Reports First Quarter Revenue of $289.0 Million and Non-GAAP Earnings Per Share of $0.28 SUNNYVALE, Calif., April 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Trimble (Nasdaq: TRMB)
More informationKforce Reports Fourth Quarter and Full Year 2011 Results
Kforce Reports Fourth Quarter and Full Year 2011 Results Fourth Quarter Revenues of $285.6 Million and EPS of $0.20 Flex Revenues Per Billing Day Increased 4.2% Sequentially Total 2011 Revenue and EPS
More informationKite Pharma Reports First Quarter 2015 Financial Results
May 15, 2015 Kite Pharma Reports First Quarter 2015 Financial Results SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company
More informationAmeresco Reports Third Quarter 2018 Financial Results
October 30, 2018 Ameresco Reports Third Quarter 2018 Financial Results Third Quarter 2018 Financial Highlights (year over year): Revenues of $205.4 million, up 0.3%, year to date of $569.8 million, up
More informationFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationAcorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016
NEWS RELEASE Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 2/14/2017 AMPYRA (dalfampridine) 4Q 2016 Net Revenue of $132 Million; Full-Year Net Revenue of $493 Million
More information1 sur 9 26/07/ :19
1 sur 9 26/07/2012 13:19 Print Page Close Window Press Releases Celgene Reports Second Quarter 2012 Operating and Financial Results Total Revenue of $1.37 Billion and Net Product Sales of $1.34 Billion,
More informationMAM Software Reports Fiscal Third Quarter Results. Delivers Steady Progress; Increases Recurring Revenue to 81% of Total Revenue
MAM Software Reports Fiscal Third Quarter Results Delivers Steady Progress; Increases Recurring Revenue to 81% of Total Revenue BARNSLEY, England, May 16, 2016 /PRNewswire/ -- MAM Software Group, Inc.
More informationHALOZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS
FOR IMMEDIATE RELEASE HALOZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS ENHANZE Licensed to Roche for up to Three Additional Targets, Includes $25 Million Upfront Payment, Plus the Potential for Future
More informationAbiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
February 1, 2018 Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year U.S. Patient Utilization Grew 33%, Year Over Year DANVERS, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) --
More informationTrimble First Quarter 2008 Revenue Up 24 Percent to $355.3 million
Trimble First Quarter 2008 Revenue Up 24 Percent to $355.3 million GAAP Earnings Per Share $0.32; Non-GAAP Earnings Per Share $0.40 SUNNYVALE, Calif., April 24, 2008 /PRNewswire-FirstCall via COMTEX News
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Revenues: Subscription $ 166,751 $ 104,878 $ 567,217 $ 349,804 Professional services and other 31,253 20,352
More informationPACCAR Inc SUMMARY STATEMENTS OF OPERATIONS (in millions except per share amounts)
SUMMARY STATEMENTS OF OPERATIONS (in millions except per share amounts) Three Months Ended September 30 Nine Months Ended September 30 Net sales and revenues $ 4,731.5 $ 3,953.2 $ 13,065.1 $ 12,079.6 Cost
More informationHealthStream Announces First Quarter 2009 Results
HealthStream Announces First Quarter 2009 Results NASHVILLE, Tenn., Apr 27, 2009 (BUSINESS WIRE) -- HealthStream, Inc. (NASDAQ: HSTM), a leading provider of learning and research solutions for the healthcare
More informationIQVIA Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationHeidelberg Pharma announces financial figures for fiscal year 2017 and provides business update
PRESS RELEASE Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update Financials in line with guidance on the back of positive revenue performance Corporate actions
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationicad REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS
icad REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Total revenues increased 17% year-over-year; up 29% excluding MRI asset sale Conference Call today at 4:30 p.m. ET NASHUA, N.H. (November 8, 2017) icad,
More informationIntuitive Surgical Announces Fourth Quarter Earnings
Intuitive Surgical Announces Fourth Quarter Earnings January 25, 2018 SUNNYVALE, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (NASDAQ:ISRG), a global technology leader in robotic-assisted,
More informationTilray, Inc. Reports Second Quarter 2018 Earnings
Reports Second Quarter 2018 Earnings August 28, 2018 Revenue rises 95.2% to US$9.7 million in second quarter and 75.2% to US$17.6 million in first half of 2018 Tilray medical cannabis products now available
More informationCytori Reports First Quarter 2014 Business and Financial Results
CYTORI THERAPEUTICS CONTACT Megan McCormick +1.858.875.5279 mmccormick@cytori.com Cytori Reports First Quarter 2014 Business and Financial Results San Diego, CA, May 12, 2014 Cytori Therapeutics (NASDAQ:
More informationSecond Quarter 2017 Financial Highlights:
Snap Inc. Reports Second Quarter 2017 Results VENICE, Calif. August 10, 2017 Snap Inc. (NYSE: SNAP) today announced financial results for the quarter ended 2017. Second Quarter 2017 Financial Highlights:
More informationHorizon Pharma Reports Third Quarter 2011 Financial Results and Provides DUEXIS Launch Update
Horizon Pharma Reports Third Quarter 2011 Financial Results and Provides DUEXIS Launch Update DEERFIELD, IL -- (MARKET WIRE) -- 11/14/11 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today reported financial
More informationMAM Software Reports Fiscal Third Quarter Results. MAM delivers steady constant currency growth
MAM Software Reports Fiscal Third Quarter Results MAM delivers steady constant currency growth BARNSLEY, England, May 15, 2017 /PRNewswire/ -- MAM Software Group, Inc. (NASDAQ Capital Market: MAMS) (the
More informationGilead Sciences Announces First Quarter 2011 Financial Results
Page 1 of 9 Gilead Sciences Announces First Quarter 2011 Financial Results - Product Sales of $1.86 Billion, Up 4 Percent over First Quarter 2010 - - Antiviral Product Sales of $1.63 Billion, Up 2 Percent
More informationIntuitive Surgical Announces Third Quarter Earnings
Intuitive Surgical Announces Third Quarter Earnings October 18, SUNNYVALE, Calif., Oct. 18, (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. ( Intuitive ) (Nasdaq: ISRG), a global technology leader in roboticassisted,
More informationAeolus Pharmaceuticals Announces First Quarter Fiscal Year 2012 Financial Results
February 13, 2012 Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2012 Financial Results MISSION VIEJO, CA -- (MARKET WIRE) -- 02/13/12 -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS:
More informationMcKESSON REPORTS FISCAL 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS
McKESSON REPORTS FISCAL 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS Revenues of $48.7 billion for the fourth quarter and $198.5 billion for the full year, up 4% year-over-year. Fourth-quarter GAAP earnings
More informationDXC Technology Delivers Third Quarter Growth in Earnings per Share, Margins, and Cash Flow
DXC Technology Delivers Third Quarter Growth in Earnings per Share, Margins, and Cash Flow Q3 Earnings per Share was $2.68, including the cumulative impact of certain items of $0.53 per share, reflecting
More informationInnophos Holdings, Inc. Reports Fourth-Quarter and Full-Year 2017 Results
Innophos Holdings, Inc. Reports Fourth-Quarter and Full-Year 2017 Results February 21, 2018 Significant Progress Advancing Vision 2022 Strategy 2017 Revenue and Earnings In-Line with Expectations Sets
More informationInternet Brands, Inc. Reports Second Quarter 2010 Financial Results
Internet Brands, Inc. Reports Second Quarter 2010 Financial Results LOS ANGELES, CA, Jul 29, 2010 (MARKETWIRE via COMTEX News Network) -- Internet Brands, Inc. (NASDAQ: INET) -- Record Revenues: $28.1
More informationMcKESSON REPORTS FISCAL 2016 SECOND-QUARTER RESULTS
McKESSON REPORTS FISCAL 2016 SECOND-QUARTER RESULTS Revenues of $48.8 billion for the second quarter, up 10%. Second-quarter GAAP earnings per diluted share from continuing operations of $2.65, up 29%.
More informationDigital River, Inc. Second Quarter Results (Unaudited, in thousands) Subject to reclassification
(Unaudited, in thousands) Condensed Consolidated Balance Sheets As of December 31, 2008 2007 Assets: Current assets Cash and cash equivalents $ 276,927 $ 381,788 Short-term investments 201,297 315,636
More informationIQVIA Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationHealthStream Announces Third Quarter 2011 Results
HealthStream Announces Third Quarter 2011 Results NASHVILLE, Tenn.--(BUSINESS WIRE)-- HealthStream, Inc. (NASDAQ: HSTM), a leading provider of learning and research solutions for the healthcare industry,
More informationCantel Medical Reports Financial Results for its Fourth Quarter Fiscal Year 2018
Cantel Medical Reports Financial Results for its Fourth Quarter Fiscal Year 2018 September 27, 2018 Strong fourth quarter closes record year in line with management expectations - Net sales of $228.9M,
More informationPERNIX THERAPEUTICS HOLDINGS, INC.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING PERNIX THERAPEUTICS HOLDINGS, INC. Form: 8-K Date Filed: 2016-11-10 Corporate Issuer CIK: 1024126 Copyright 2016, Issuer Direct Corporation. All Right Reserved.
More informationAeolus Announces Second Quarter Financial Results for Fiscal Year 2017
May 15, 2017 Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017 MISSION VIEJO, CA -- (Marketwired) -- 05/15/17 -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company
More informationAffimed Reports Financial Results for Second Quarter 2018 and Operational Progress
FOR IMMEDIATE RELEASE Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress Heidelberg, Germany, August 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical
More informationSunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights. VALOR Trial Reaches Prespecified Events for Unblinding
Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights August 5, 2014 7:00 AM ET VALOR Trial Reaches Prespecified Events for Unblinding Sunesis to Host Conference Call
More informationEDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS. IRVINE, Calif., October 23, 2018 Edwards Lifesciences Corporation (NYSE: EW), the global leader in
Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact:
More informationDIPLOMAT PHARMACY, INC.
DIPLOMAT PHARMACY, INC. FORM 8-K (Current report filing) Filed 05/11/15 for the Period Ending 05/11/15 Address 4100 S. SAGINAW ST. FLINT, MI 48507 Telephone 888-720-4450 CIK 0001610092 Symbol DPLO SIC
More informationPremier Inc. Reports Fiscal 2017 First-Quarter Results
NEWS RELEASE Premier Inc. Reports Fiscal 2017 First-Quarter Results 11/7/2016 CHARLOTTE, N.C.--(BUSINESS WIRE)-- Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2017 first quarter
More informationGlobus Medical Reports 2014 First Quarter Results
Globus Medical Reports First Quarter Results AUDUBON, PA, April 29, : Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial results for the first
More informationHOLOGIC ANNOUNCES THIRD QUARTER FISCAL 2009 OPERATING RESULTS. Solid Quarterly Revenues and Performance
For Immediate Release Contact: Deborah R. Gordon Vice President, Investor Relations Hologic, Inc. (781) 999-7716 HOLOGIC ANNOUNCES THIRD QUARTER FISCAL 2009 OPERATING RESULTS Solid Quarterly Revenues and
More informationICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2015 Results
February 3, 2016 ICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2015 Results Fiscal Year 2015 Adjusted EBITDA Increased 54% to $114 Million SAN CLEMENTE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE)
More informationFTD Companies, Inc. Announces Third Quarter 2014 Financial Results
November 12, 2014 FTD Companies, Inc. Announces Third Quarter 2014 Financial Results Company Reports Third Quarter 2014 Consolidated Revenues of $125.1 Million Company Reports Third Quarter 2014 Net Income
More informationInvestors: Gilead News Release. Gilead Sciences Announces Second Quarter 2010 Financial Results
Page 1 sur 7 Gilead Sciences Announces Second Quarter 2010 Financial Results - Total Revenues of $1.93 Billion, Up 17 Percent over Second Quarter 2009 - - Product Sales of $1.81 Billion, Up 15 Percent
More informationDXC Technology Delivers Strong Second Quarter Results with Growth in Earnings per Share, Margins, and Cash Flow
DXC Technology Delivers Strong Second Quarter Results with Growth in Earnings per Share, Margins, and Cash Flow Q2 Earnings per Share was $0.88, including the cumulative impact of certain items of $1.05
More informationWilliams Industrial Services Group Reports 37% Increase in Revenue for Third Quarter 2018
Williams Industrial Services Group Reports 37% Increase in Revenue for Third Quarter 2018 November 9, 2018 Revenue increased 37% to $53.5 million driven by nuclear construction projects Gross margin was
More informationZscaler Reports Third Quarter Fiscal 2018 Financial Results
Zscaler Reports Third Quarter Fiscal 2018 Financial Results Revenue grows 49% year over year to $49.2 million Calculated billings grow 73% year over year to $54.7 million Deferred revenue grows 61% year
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Revenues: Subscription $ 179,907 $ 117,375 Professional services and other 32,057 21,715 Total revenues 211,964
More informationCYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported)
More informationSelling, general and administrative expenses 35,645 33,787. Net other operating income (292) (270) Operating profit 44,202 17,756
Condensed Interim Consolidated Income Statement For the quarter ended September 30 Continuing operations Revenue 328,071 258,941 Cost of sales 248,516 207,668 Gross profit 79,555 51,273 Selling, general
More informationNU SKIN ENTERPRISES REPORTS RECORD FOURTH-QUARTER AND 2010 RESULTS
FOR IMMEDIATE RELEASE CONTACTS: Investors Scott Pond, (801) 345-2657, spond@nuskin.com Media Kara Schneck, (801) 345-2116, kschneck@nuskin.com NU SKIN ENTERPRISES REPORTS RECORD FOURTH-QUARTER AND 2010
More informationClean Energy Reports Third Quarter 2007 Financial Results
Clean Energy Reports Third Quarter 2007 Financial Results SEAL BEACH, Calif., Nov 12, 2007 (BUSINESS WIRE) -- Clean Energy Fuels Corp. (NASDAQ:CLNE) today announced financial results for the three and
More informationMcKESSON REPORTS FISCAL 2018 THIRD-QUARTER RESULTS
McKESSON REPORTS FISCAL 2018 THIRD-QUARTER RESULTS Revenues of $53.6 billion for the third quarter, up 7% year-over-year. Third-quarter GAAP earnings per diluted share from continuing operations of $4.32,
More informationNeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017
July 25, 2017 NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 Significant Improvement in Gross Margin FT.
More informationMAM Software Reports Fiscal Fourth Quarter and Full Year Results. MAM ends the fiscal year with strong results and recurring revenues grows to 83%
MAM Software Reports Fiscal Fourth Quarter and Full Year Results MAM ends the fiscal year with strong results and recurring revenues grows to 83% BLUE BELL, Pennsylvania, September 28, 2017 /PRNewswire/
More informationBeacon Roofing Supply Reports First Quarter 2014 Results
February 7, 2014 Beacon Roofing Supply Reports First Quarter 2014 Results Record first quarter sales of $552.1 million vs. $513.7 million in prior year (7.5% growth) First quarter EPS of $0.30 vs. $0.37
More information